Nanoparticle-Directed Photothermal Ablation of Primary Brain Tumors guided by Mag

Mag 引导的纳米粒子定向光热消融原发性脑肿瘤

• 批准号: 8110640
• 负责人: R JASON STAFFORD
• 金额: $ 44.5万
• 依托单位: NANOSPECTRA BIOSCIENCES, INC.
• 依托单位国家: 美国
• 财政年份: 2010
• 资助国家: 美国
• 起止时间: 2010-07-12 至 2013-04-30
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/8110640
• 关键词: Ablation; Acute; Adverse effects; Animals; Area; Brain; Brain Neoplasms; Breeding; Cancer Center; Cancer Patient; Canis familiaris; Cells; Childhood; Chronic; Clinical Protocols; Clinical Trials; Comorbidity; Conflict (Psychology); Contralateral; Cultured Cells; Diffusion; Disorder by Site; Engraftment; Evaluation; Feasibility Studies; Fiber; Glioma; Gold; Growth; Headache; Histopathology; Hour; Human; Image; Imaging technology; Immunosuppression; In Vitro; Incidence; Infusion procedures; Intracranial Pressure; Lasers; Lead; Lesion; Long-Term Effects; Magnetic Resonance; Magnetic Resonance Imaging; Malignant Neoplasms; Maps; Measures; Modality; Modeling; Monitor; Morbidity - disease rate; Nature; Neoplasm Metastasis; Operative Surgical Procedures; Optics; Outcome; Pathology; Patients; Positioning Attribute; Primary Brain Neoplasms; Primary Neoplasm; Process; Quality of life; Radiation therapy; Radiosurgery; Recurrence; Research Project Grants; Sampling; Second Primary Neoplasms; Seizures; Shapes; Skull Base Neoplasms; Solid Neoplasm; Source; Specificity; System; Techniques; Technology; Temperature; Time; Tissues; Translating; Treatment Protocols; Tumor Volume; Ultrasonography; Work; base; brain tissue; cancer therapy; chemotherapy; clinical application; cranium; cryogenics; cytotoxicity; dosimetry; glioma cell line; image guided therapy; improved; in vivo; irradiation; microwave electromagnetic radiation; minimally invasive; nanoparticle; novel; particle; public health relevance; radiofrequency; relating to nervous system; response; success; treatment duration; treatment planning; tumor; uptake

DESCRIPTION (provided by applicant): The incidence of brain tumors in the U.S., including primary and metastases of other cancers, is estimated to be around 200,000 per year. Current treatments consist of open surgery, radiation, and chemotherapy, but these treatments are by no means curative for most patients and result in substantial side effects for some patients. There is a significant need for therapies that improve outcomes with fewer side effects than current therapies, but which are also synergistic with current approaches. We have previously completed a feasibility study of a minimally invasive, nanoparticle-directed, image- guided therapy for the photothermal ablation of solid tumors in a canine brain tumor model. This proposed research project will translate these preliminary studies into a clinical application and provide the basis for a human clinical trial at the conclusion of the project. Using a canine glioma cell line, we will demonstrate that systemically-delivered, infrared absorbing nanoparticles will self-select for the tumor boundary. Using Magnetic Resonance temperature imaging, we will demonstrate that the photothermal ablation can be confined to a tumor-specific treatment zone, resulting in clear margins with minimal damage to adjacent neural tissue. The selectivity of this therapy will be assessed by acute (48-72 hour) pathology and longer (6 week) survival studies. The minimally-invasive nature of the percutaneous photothermal treatment should lead to an enhancement of patients' quality of life as a result of reduced tumor volume and reduced intracranial pressure, which should reduce the incidence of seizures and headaches. And, a lowered morbidity in cancer patients would permit other treatments such as chemotherapy which do not conflict with this photothermal therapy. Additionally, a minimally invasive, percutaneously delivered photothermal therapy may permit treatment of non-resectable deeper or skull-based tumors. PUBLIC HEALTH RELEVANCE: The incidence of brain tumors in the U.S., including primary and metastases of other cancers, is approximately 200,000 per year. The currently accepted treatment modalities for tumors of the brain include surgery, whole-brain radiotherapy, stereotactic radiosurgery, chemotherapy; or some combination of these, but these treatments are by no means curative for most patients and result in substantial side effects for some patients. We will develop a minimally invasive therapy to eliminate or reduce in size primary tumors in the brain and skull, improving outcomes and reducing morbidity.

描述（由申请人提供）：美国脑肿瘤的发病率，包括其他癌症的原发性和转移，估计约为200,000。当前的治疗方法包括开放手术，放射线和化学疗法，但这些治疗对大多数患者来说绝不是治愈性的，对某些患者产生了重大副作用。比目前的疗法相比，对改善副作用更少的副作用的疗法有很大的需求，但与当前方法也是协同作用。我们先前已经完成了对犬脑肿瘤模型中实体瘤的光热消融的最小侵入性，纳米颗粒导向的，图像引导的治疗的可行性研究。该提出的研究项目将把这些初步研究转化为临床应用，并在该项目结束时为人类临床试验提供了基础。使用犬神经胶质瘤细胞系，我们将证明，肿瘤边界会自我选择，全身递送的红外吸收纳米颗粒。使用磁共振温度成像，我们将证明光热消融可以局限于肿瘤特异性治疗区，从而导致清晰的边缘对相邻神经组织的损害极小。该疗法的选择性将通过急性（48-72小时）病理和更长的（6周）生存研究来评估。经皮光热治疗的最小侵入性性质应导致患者的生活质量增强，因为肿瘤体积减少和颅内压力降低，这应降低癫痫发作和头痛的发生率。并且，癌症患者的发病率降低将允许其他疗法，例如与这种光热疗法不冲突的化学疗法。此外，一种微创的，经皮的光热疗法可以允许治疗不可切除的深层或颅底肿瘤。 公共卫生相关性：美国脑肿瘤的发病率，包括其他癌症的原发性和转移，每年约200,000。目前对大脑肿瘤的接受治疗方式包括手术，全脑放射疗法，立体定向放射外科手术，化学疗法；或某些组合，但是这些治疗对大多数患者来说绝不是治愈性的，对某些患者产生了重大副作用。我们将开发一种微创疗法，以消除或减少大脑和头骨中大小的原发性肿瘤，改善预后并降低发病率。